STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery (STRATAGEM)
Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery
Study Overview
Detailed Description
There is little evidence to guide antiplatelet therapy in patients at high risk of atherothrombotic events undergoing non cardiac surgery. Specifically, it is uncertain whether patients currently on antiplatelet therapy should continue or not continue treatment in the perioperative period.
Aim: To determine an evidence-based strategy for managing antiplatelet therapy in the perioperative period.
Methods: The STRATAGEM trial is an investigator-driven French nationwide multicenter, randomized, double-blind, placebo-controlled trial comparing perioperative low-dose aspirin therapy versus placebo in the perioperative period in patients with documented symptomatic stable atherothrombotic disease taking antiplatelet therapy and undergoing non-coronary surgery. The trial will involve 1500 patients at high risk of atherothrombosis, currently receiving long-term antiplatelet therapy and scheduled for non-coronary surgery in 50 centers. Ten days prior to surgery, patients will discontinue antiplatelet therapy and be randomly assigned to either 75 mg of aspirin or matching placebo for 10 days up to the surgical procedure. Usual therapy will be resumed after surgery according to local practice.
The main outcome measure will be a composite endpoint at day 30 reflecting serious perioperative complications, i.e. total mortality, severe ischemic events (ischemic stroke, non-fatal myocardial infarction [MI], acute limb ischemia, clinical deep venous thrombosis) and/or major hemorrhage (life-threatening bleeding or conducive to revision, or redo surgery, cerebral hemorrhage, intra- or retroperitoneal bleeding, bleeding resulting in the transfusion of more than 2 units of packed red blood cells). The hypothesis to be tested is that low-dose aspirin is associated with a net clinical benefit compared to placebo in the prevention of severe perioperative thrombotic and hemorrhagic complications.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Clichy, France, 92110
- Hopital Beaujon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Patients over eighteen years of age
Patients treated with oral antiplatelet agents for secondary prevention (i.e. established and symptomatic cardiovascular disease):
- regardless of the reason (coronary artery disease, stroke or TIA [transient ischemic attack], peripheral arterial disease)
- regardless of the antiplatelet agent (aspirin, clopidogrel, ticlopidine, dipyridamole).
Patients scheduled for intermediate or high-risk surgery, including but not limited to:
- any long procedure associated with hemodynamic variations or major blood loss
- valvular surgery
- thoracic surgery
- orthopedic surgery
- general (intraperitoneal) surgery
- urological surgery
- vascular surgery
- ear, nose, and throat (ENT) cancerology-related surgery.
Exclusion Criteria:
- Coronary bypass grafting surgery
- History of thrombocytopenia or allergy to heparin
- Arterial stent placement within the previous 30 days
- Active bleeding
- Formal contraindication to the use of anticoagulants and aspirin
- Recent acute coronary syndrome
- Ophthalmological surgery (posterior chamber)
- Neurosurgery
- Emergency surgery
- Thrombotic or bleeding risk deemed unacceptable by the surgical and anesthetic team
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Aspirin:KARDEGIC
|
aspirin 75 mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Consisting of major thromboembolic events listed in the following table with their respective weights.
Time Frame: A composite criterion measured at Day 30
|
The score allocated to each patient is the weight of the event (zero if no event has occurred).
For the patients having experienced more than one event, the score attributed is the "heaviest" weight among the events he has undergone.
|
A composite criterion measured at Day 30
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jean Mantz, MD, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thrombosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- P030440
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.